当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
GAVRETO (pralsetinib) 400 mg (once daily)
申请企业
BLUEPRINT MEDICINES CORP
药品名称
GAVRETO (pralsetinib) 400 mg (once daily)
承诺描述
Conduct a rodent carcinogenicity study of pralsetinib in rats to evaluate its potential for carcinogenicity. Submit a carcinogenicity protocol for a Special Protocol Assessment (SPA) prior to initiating the study.